Shenzhen Chipscreen Biosciences Co (SHG:688321) — Market Cap & Net Worth
Market Cap & Net Worth: Shenzhen Chipscreen Biosciences Co (688321)
Shenzhen Chipscreen Biosciences Co (SHG:688321) has a market capitalization of $1.50 Billion (CN¥10.22 Billion) as of June 17, 2026. Listed on the SHG stock exchange, this China-based company holds position #7395 globally and #1697 in its home market, demonstrating a 3.21% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Chipscreen Biosciences Co's stock price CN¥25.06 by its total outstanding shares 407807559 (407.81 Million). Review Shenzhen Chipscreen Biosciences Co balance sheet liabilities to assess the company's total debt and financial obligations.
Shenzhen Chipscreen Biosciences Co Market Cap History: 2019 to 2026
Shenzhen Chipscreen Biosciences Co's market capitalization history from 2019 to 2026. Data shows change from $3.35 Billion to $1.50 Billion (-17.72% CAGR).
Shenzhen Chipscreen Biosciences Co Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Chipscreen Biosciences Co's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.69x
Shenzhen Chipscreen Biosciences Co's market cap is 1.69 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $3.35 Billion | $173.80 Million | $19.42 Million | 19.26x | 172.37x |
| 2020 | $2.21 Billion | $269.47 Million | $31.05 Million | 8.20x | 71.14x |
| 2021 | $2.09 Billion | $430.45 Million | $21.96 Million | 4.85x | 95.15x |
| 2022 | $1.31 Billion | $529.94 Million | $17.48 Million | 2.48x | 75.02x |
| 2023 | $1.31 Billion | $523.71 Million | $88.84 Million | 2.50x | 14.74x |
| 2024 | $1.11 Billion | $657.95 Million | -$114.57 Million | 1.69x | N/A |
Competitor Companies of 688321 by Market Capitalization
Companies near Shenzhen Chipscreen Biosciences Co in the global market cap rankings as of June 17, 2026.
Key companies related to Shenzhen Chipscreen Biosciences Co by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #561 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #624 globally with a market cap of $44.20 Billion USD ( CN¥302.05 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #635 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #561 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.22 |
| #624 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $44.20 Billion | CN¥47.35 |
| #635 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.60 |
Shenzhen Chipscreen Biosciences Co Historical Marketcap From 2019 to 2026
Between 2019 and today, Shenzhen Chipscreen Biosciences Co's market cap moved from $3.35 Billion to $ 1.50 Billion, with a yearly change of -17.72%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥1.50 Billion | -14.24% |
| 2025 | CN¥1.74 Billion | +57.27% |
| 2024 | CN¥1.11 Billion | -15.35% |
| 2023 | CN¥1.31 Billion | -0.14% |
| 2022 | CN¥1.31 Billion | -37.22% |
| 2021 | CN¥2.09 Billion | -5.40% |
| 2020 | CN¥2.21 Billion | -34.03% |
| 2019 | CN¥3.35 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 17th, 2026 the market cap of Shenzhen Chipscreen Biosciences Co was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.50 Billion USD |
| MoneyControl | $1.50 Billion USD |
| MarketWatch | $1.50 Billion USD |
| marketcap.company | $1.50 Billion USD |
| Reuters | $1.50 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Chipscreen Biosciences Co
Shenzhen Chipscreen Biosciences Co., Ltd. engages in the research and development of original small molecule drugs. The company develops Chidamide, a subtype-selective histone deacetylase inhibitor for the treatment of peripheral T-cell lymphoma and advanced hormone receptor-positive breast cancer; Chiglitazar Sodium, a PPAR pan-agonist for the treatment of metabolic diseases; and Chiauranib, a t… Read more